Most Recent
Maurice Blackburn owes State Street royalties for Fearless Girl replica, court hears
Intellectual Property 2019-08-06 1:32 pm By Christine Caulfield

US investment manager State Street Global Advisors claims it lost out on royalties when Maurice Blackburn commissioned an allegedly infringing replica of its iconic Fearless Girl statue in New York City, a marketing phenomenon that has been estimated to be valued at up to $38.6 million.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

BASF termite control patent invalid, court told
Intellectual Property 2019-07-09 3:50 pm By Miklos Bolza

Sherwood Chemicals wants to exterminate claims alleging it infringed two patents held by US chemical giant BASF for an underground termite control system, saying the patents were invalid and that any infringement, if it occurred, was innocent.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Teva, Boehringer settle inhaler capsule patent dispute
Intellectual Property 2019-06-19 2:56 pm By Miklos Bolza

Israeli drug giant Teva and German drug maker Boehringer Ingelheim have settled their dispute over a patented capsule used to deliver the medicine in Boehringer’s top-selling inhaler Spiriva.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Bayer faces appeals of IP Australia rulings on antiseptic patent
Intellectual Property 2019-06-04 3:24 pm By Miklos Bolza

Veterinary pharmaceutical companies Norbrook Laboratories and Merial have launched twin appeals of two IP Australia decisions allowing Bayer to amend a proposed patent for a treatment for mammary gland infections.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Novartis patent for oral form of top-selling MS drug obvious, IP Australia says
Intellectual Property 2019-05-13 12:31 pm By Miklos Bolza

A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has found, but gave the pharmaceutical giant a chance to amend.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?